CytoDyn (OTCQB: CYDY) has announced the release of their poster presentation at the European Society for Medical Oncology (ESMO) Breast Cancer meeting taking place from May 14-17, 2025, in Munich, Germany. The poster discusses their drug candidate leronlimab, a CCR5 antagonist being developed for multiple therapeutic indications. The presentation focuses on leronlimab's novel mechanism of action in treating solid tumors, with detailed data referenced in the company's previous press release from May 13, 2025.
CytoDyn (OTCQB: CYDY) ha annunciato la pubblicazione del proprio poster al European Society for Medical Oncology (ESMO) Breast Cancer meeting, che si terrà dal 14 al 17 maggio 2025 a Monaco di Baviera, Germania. Il poster presenta il loro candidato farmaco leronlimab, un antagonista del CCR5 in fase di sviluppo per diverse indicazioni terapeutiche. La presentazione si concentra sul nuovo meccanismo d'azione di leronlimab nel trattamento dei tumori solidi, con dati dettagliati riportati nel comunicato stampa precedente dell'azienda del 13 maggio 2025.
CytoDyn (OTCQB: CYDY) ha anunciado la publicación de su presentación en formato póster en la Reunión de la Sociedad Europea de Oncología Médica (ESMO) sobre Cáncer de Mama, que se llevará a cabo del 14 al 17 de mayo de 2025 en Múnich, Alemania. El póster aborda su candidato a fármaco leronlimab, un antagonista de CCR5 que se está desarrollando para múltiples indicaciones terapéuticas. La presentación se centra en el novedoso mecanismo de acción de leronlimab en el tratamiento de tumores sólidos, con datos detallados referenciados en el comunicado de prensa previo de la compañía del 13 de mayo de 2025.
CytoDyn(OTCQB: CYDY)는 2025년 5월 14일부터 17일까지 독일 뮌헨에서 열리는 유럽종양학회(ESMO) 유방암 회의에서 포스터 발표를 공개했다고 발표했습니다. 이 포스터는 다양한 치료 적응증을 위해 개발 중인 CCR5 길항제인 leronlimab 후보 약물을 다루고 있습니다. 발표는 고형 종양 치료에서 leronlimab의 새로운 작용 기전에 초점을 맞추고 있으며, 자세한 데이터는 회사가 2025년 5월 13일에 발표한 이전 보도자료에 참고되어 있습니다.
CytoDyn (OTCQB : CYDY) a annoncé la publication de sa présentation sous forme d'affiche lors de la réunion de la Société Européenne d'Oncologie Médicale (ESMO) sur le cancer du sein, qui se tiendra du 14 au 17 mai 2025 à Munich, en Allemagne. L'affiche présente leur candidat médicament leronlimab, un antagoniste du CCR5 en développement pour plusieurs indications thérapeutiques. La présentation met l'accent sur le mécanisme d'action novateur de leronlimab dans le traitement des tumeurs solides, avec des données détaillées référencées dans le communiqué de presse précédent de la société du 13 mai 2025.
CytoDyn (OTCQB: CYDY) hat die Veröffentlichung ihrer Posterpräsentation auf dem European Society for Medical Oncology (ESMO) Breast Cancer Meeting bekannt gegeben, das vom 14. bis 17. Mai 2025 in München, Deutschland, stattfindet. Das Poster behandelt ihren Arzneimittelkandidaten leronlimab, einen CCR5-Antagonisten, der für verschiedene therapeutische Indikationen entwickelt wird. Die Präsentation konzentriert sich auf den neuartigen Wirkmechanismus von leronlimab bei der Behandlung solider Tumore, mit detaillierten Daten, die in der vorherigen Pressemitteilung des Unternehmens vom 13. Mai 2025 referenziert werden.
Positive
None.
Negative
None.
VANCOUVER, Washington, May 15, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today shared the Company’s poster presented at the European Society for Medical Oncology’s (“ESMO”) Breast Cancer meeting on May 14-17, 2025, in Munich, Germany.
More information about the data CytoDyn presented at ESMO suggesting the novel mechanism of action of leronlimab for the treatment of solid tumors can be found in the Company’s press release issued on May 13, 2025.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes. CytoDyn has studied leronlimab in multiple therapeutic areas, including oncology, infectious disease, and autoimmune conditions.
Note Regarding Forward-Looking Statements
This news release may contain forward-looking statements relating to, among other things, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2024, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.
What did CytoDyn (CYDY) present at ESMO Breast Cancer Meeting 2025?
CytoDyn presented a poster discussing leronlimab, their CCR5 antagonist drug candidate, focusing on its novel mechanism of action for treating solid tumors.
What is leronlimab and what is it being developed for by CytoDyn?
Leronlimab is a CCR5 antagonist being developed by CytoDyn for multiple therapeutic indications, including the treatment of solid tumors.
When and where was the ESMO Breast Cancer Meeting 2025 held?
The ESMO Breast Cancer Meeting 2025 was held from May 14-17, 2025, in Munich, Germany.
What is CytoDyn's stock symbol and exchange?
CytoDyn trades under the symbol CYDY on the OTCQB market.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
